A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States

Drug and Alcohol Dependence

Volumn 73, Issue 3, 2004, Pages 227-236

  Strauss, Shiela M ^a   Astone, Janetta M ^a   Des Jarlais, Don ^b   Hagan, Holly ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Drug treatment programs; Health services; Hepatitis C; Methadone maintenance; Screening

Indexed keywords

HEPATITIS C ANTIBODY;

ANTIBODY SCREENING; ARTICLE; HEPATITIS C VIRUS; HUMAN; METHADONE TREATMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SUBSTANCE ABUSE; UNITED STATES;

HEPATITIS C VIRUS;

EID: 1242314709     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2003.08.009     Document Type: Article

References (45)

1. Aitken C.K., Kerger M., Crofts N. Peer-delivered hepatitis C testing and counselling: a means of improving the health of injecting drug users. Drug Alcohol Rev. 21:2002;33-37.
2. Alter M.J. Epidemiology of hepatitis C. Hepatology. 26:1997;62S-65S.
3. Alter M.J. Prevention of spread of hepatitis C. Hepatology. 36(5 (Suppl. 1)):2002;S93-S98.
4. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:1999;556-562.
5. Alter M.J., Moyer L.A. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune Defic. Syndr. 18:1998;S6-S10.
6. Bae J.P. Assessing the need, use, and developments in mental health/substance abuse care. Health Care Financ. Rev. 18:1997;1-4.
7. Best D., Noble A., Finch E., Gossop M., Sidwell C., Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br. Med. J. 319:1999;290-291.
8. Centers for Disease Control and Prevention, 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47, 1-39.
9. Chitwood D.D., McBride D.C., French M.T., Comerford M. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Subst. Use Misuse. 34:1999;727-746.
10. Contoreggi C., Rexroad V.E., Lange W.R. Current management of infectious complications in the injecting drug user. J. Subst. Abuse Treat. 15:1998;95-106.
11. D'Aunno T., Vaughn T.E., McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. J. Health Soc. Behav. 40:1999;175-192.
12. D'Aunno T.A., Vaughn T.E. An organizational analysis of service patterns in outpatient drug abuse treatment units. J. Subst. Abuse. 7:1995;27-42.
13. Des Jarlais D.C., Stimson G.V., Hagan H., Perlman D., Choopanya K., Bastos F.I., Friedman S.R. Emerging infectious diseases and the injection of illicit psychoactive drugs. Curr. Issues Public Health. 2:1996;130-137.
14. Dhopesh V.P., Taylor K.R., Burke W.M. Survey of hepatitis B and C in an addiction treatment unit. Am. J. Drug Alcohol Abuse. 26:2000;703-707.
15. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:2002;975-982.
16. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune Defic. Syndr. 18(Suppl. 1):1998;S11-S19.
17. Gordon F.D. Cost-effectiveness of screening patients for hepatitis C. Am. J. Med. 107:1999;36S-40S.
18. Grando-Lemaire V., Goisset P., Sorge F., Trinchet J.C., Castera L., Roulot D., Sitruk V., Beaugrand M. Hepatitis C virus screening in drug users in an addiction out-patient unit. Gastroenterol. Clin. Biol. 26:2002;1091-1096.
19. Hagan H., McGough J.P., Thiede H., Weiss N.S., Hopkins S., Alexander E.R. Syringe exchange and risk of HBV and HCV in Seattle IDUs. Am. J. Epidemiol. 149:1999;203-213.
20. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health. 91:2001;42-46.
21. Hahn J.A., Page-Shafer K., Lum P.J., Ochoa K., Moss A.R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 34:2001;180-187.
22. Heimer R., Clair S., Grau L.E., Bluthenthal R.N., Marshall P.A., Singer M. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction. 97:2002;1277-1287.
23. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology. 26:1997;15S-20S.
24. Kim W.R. The burden of hepatitis C in the United States. Hepatology. 36:2002;S30-S34.
25. Kwiatkowski C.F., Corsi K.F., Booth R.E. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 97:2002;1289-1294.
26. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:2000;296-305.
27. Lorvick J., Kral A.H., Seal K., Gee L., Edlin B.R. Prevalence and duration of hepatitis C among injection drug users in San Francisco, California. Am. J. Public Health. 91:2001;46-47.
28. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
29. McCarthy J.J., Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J. Addict. Dis. 20:2001;19-31.
30. National Institutes of Health, 2002. In: proceedings of the National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. 10-12 June 2002; Hepatology 36, S3-S20.
31. Needle R.H., Coyle S., Normand J., Lambert E., Cesari H. HIV prevention with drug-using populations-current status and future prospects: introduction and overview. Public Health Rep. 113:1998;4-18.
32. Polinsky M.L., Hser Y.-I., Anglin M.D., Maglione M.A. Drug-user treatment programs in a large metropolitan area. Subst. Use Misuse. 33:1998;1735-1761.
33. Pratt C.-C.N.U., Paone D., Carter B.J., Layton M.C. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. Am. J. Public Health. 92:2002;1254-1256.
34. Rosenberg S.D., Goodman L.A., Osher F.C. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am. J. Public Health. 91:2001;42-46.
35. Rosenblum A., Nuttbrock L., McQuistion H.L., Magura S., Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J. Addict. Dis. 20:2001;15-25.
36. Selwyn P.A., Budner N.S., Wasserman W.C., Arno P.S. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 108:1993;492-500.
37. Smyth B.P., Keenan E., O'Connor J.J. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. Ir. J. Med. Sci. 169:2000;129-132.
38. Stein M.D., Maksad J., Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 61:2001;211-215.
39. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., Monterroso E.R. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am. J. Epidemiol. 155:2002;645-653.
40. Tortu S., Neaigus A., McMahon J., Hagen D. Hepatitis C among non-injecting drug users: a report. Subst. Use Misuse. 36:2001;523-534.
41. Umbricht-Schneiter A., Ginn D.H., Pabst K.M., Bigelow E. Providing medical care to methadone clinic patients: referral vs. on-site care. Am. J. Public Health. 84:1994;207-210.
42. Waite J. The laboratory diagnosis of the hepatitis viruses. Int. J. STD AIDS. 7:1996;400-408.
43. Williams I. Epidemiology of hepatitis C in the United States. Am. J. Med. 107:1999;2S-9S.
44. Winstock A.R., Sheridan J., Lovell S., Farrell M., Strang J. National survey of hepatitis testing and vaccination services provided by drug services in England and Wales. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;823-828.
45. Zanetti A.R., Romano L., Bianchi S. Primary prevention of hepatitis C virus infection. Vaccine. 21:2003;692-695.